CR10213A - Moduladores de la proteína quinasa aurora - Google Patents

Moduladores de la proteína quinasa aurora

Info

Publication number
CR10213A
CR10213A CR10213A CR10213A CR10213A CR 10213 A CR10213 A CR 10213A CR 10213 A CR10213 A CR 10213A CR 10213 A CR10213 A CR 10213A CR 10213 A CR10213 A CR 10213A
Authority
CR
Costa Rica
Prior art keywords
quinasa
modulators
aurora protein
aurora
protein
Prior art date
Application number
CR10213A
Other languages
English (en)
Inventor
Victor J Cee
Holly L Deak
Bingfan Du
Stephanie D Geuns-Meyer
Brian L Hodous
Hanh Nho Nguyen
Philip R Olivieri
Vinod F Patel
Karina Romero
Laurie Schenkel
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/655,642 external-priority patent/US7560551B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR10213A publication Critical patent/CR10213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos y composiciones útiles para modular la proteína quinasa Aurora, según la fórmula
CR10213A 2006-01-23 2008-08-18 Moduladores de la proteína quinasa aurora CR10213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76167506P 2006-01-23 2006-01-23
US11/655,642 US7560551B2 (en) 2006-01-23 2007-01-18 Aurora kinase modulators and method of use

Publications (1)

Publication Number Publication Date
CR10213A true CR10213A (es) 2008-10-03

Family

ID=40849087

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10213A CR10213A (es) 2006-01-23 2008-08-18 Moduladores de la proteína quinasa aurora

Country Status (21)

Country Link
EP (1) EP1984353B1 (es)
JP (2) JP5280862B2 (es)
KR (2) KR101332975B1 (es)
AU (2) AU2007208351C1 (es)
BR (1) BRPI0706684A2 (es)
CA (1) CA2637658C (es)
CR (1) CR10213A (es)
DK (1) DK1984353T3 (es)
EA (1) EA018128B1 (es)
ES (1) ES2502790T3 (es)
GE (1) GEP20125643B (es)
HK (1) HK1167140A1 (es)
HR (1) HRP20160039T1 (es)
HU (1) HUE028504T2 (es)
IL (1) IL192812A (es)
MA (1) MA30224B1 (es)
MY (1) MY161884A (es)
NO (1) NO20083639L (es)
NZ (1) NZ569815A (es)
TN (1) TNSN08310A1 (es)
WO (1) WO2007087276A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5280862B2 (ja) * 2006-01-23 2013-09-04 アムジエン・インコーポレーテツド オーロラキナーゼ調節剤および使用方法
AU2008236670B2 (en) * 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use
US8404694B2 (en) 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010017240A2 (en) * 2008-08-04 2010-02-11 Amgen Inc. Aurora kinase modulators and methods of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
CA2746307C (en) 2008-12-17 2013-11-19 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
WO2010144647A1 (en) 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
RS53807B1 (en) 2009-09-11 2015-06-30 Amgen Inc. N- (4 - ((3- (2-AMINO-4-Pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of cancer resistant ANTIMITOTIC AGENCIES
ES2620521T3 (es) 2011-03-23 2017-06-28 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
CA2932560C (en) * 2013-12-03 2022-11-15 Amgen Inc. Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof
ES2739526T3 (es) 2015-06-03 2020-01-31 Bristol Myers Squibb Co Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
EP3351533A4 (en) 2015-09-18 2019-03-06 Kaken Pharmaceutical Co., Ltd. BIARY DERIVATIVE AND MEDICAMENT THEREOF
JP7032903B2 (ja) * 2016-10-12 2022-03-09 田辺三菱製薬株式会社 スルホンアミド化合物の製造方法
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN111302948A (zh) * 2020-04-13 2020-06-19 长兴进源新材料科技有限公司 一种2,2-双(4-氨基苯基)六氟丙烷合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003436A (es) * 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
NZ522696A (en) 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
PL211694B1 (pl) 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US20050203110A1 (en) 2002-05-23 2005-09-15 Coleman Paul J. Mitotic kinesin inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
FR2853378B1 (fr) 2003-04-02 2006-03-10 Carbone Lorraine Composants Plaquettes de frein a disque ventilees
WO2005063738A1 (ja) 2003-12-29 2005-07-14 Banyu Pharmaceutical Co.,Ltd 新規２－へテロアリール置換ベンズイミダゾール誘導体
JP5097539B2 (ja) * 2004-05-07 2012-12-12 アムジエン・インコーポレーテツド タンパク質キナーゼ調節剤および使用方法
JP5280862B2 (ja) * 2006-01-23 2013-09-04 アムジエン・インコーポレーテツド オーロラキナーゼ調節剤および使用方法

Also Published As

Publication number Publication date
HRP20160039T1 (hr) 2016-02-12
KR20080095889A (ko) 2008-10-29
WO2007087276A1 (en) 2007-08-02
AU2010241280B2 (en) 2013-02-28
MA30224B1 (fr) 2009-02-02
MY161884A (en) 2017-05-15
BRPI0706684A2 (pt) 2011-04-05
IL192812A (en) 2014-06-30
AU2007208351B2 (en) 2010-08-05
AU2007208351A1 (en) 2007-08-02
EA200801732A1 (ru) 2009-02-27
CA2637658C (en) 2012-07-17
KR101300424B1 (ko) 2013-08-26
IL192812A0 (en) 2009-02-11
KR20110133056A (ko) 2011-12-09
HUE028504T2 (en) 2016-12-28
AU2007208351C1 (en) 2011-07-07
EP1984353B1 (en) 2015-12-30
AU2010241280A1 (en) 2010-11-25
JP5280862B2 (ja) 2013-09-04
HK1167140A1 (en) 2012-11-23
JP5753546B2 (ja) 2015-07-22
JP2009528268A (ja) 2009-08-06
GEP20125643B (en) 2012-09-25
JP2013136585A (ja) 2013-07-11
NZ569815A (en) 2011-11-25
NO20083639L (no) 2008-10-22
EA018128B1 (ru) 2013-05-30
DK1984353T3 (en) 2016-03-14
TNSN08310A1 (en) 2009-12-29
EP1984353A1 (en) 2008-10-29
KR101332975B1 (ko) 2013-11-25
CA2637658A1 (en) 2007-08-02
ES2502790T3 (es) 2014-10-06

Similar Documents

Publication Publication Date Title
CR10213A (es) Moduladores de la proteína quinasa aurora
ECSP088854A (es) Moduladores bencimidazolicos de vr1
EA201100037A1 (ru) Органические соединения
EA200970156A1 (ru) Пиридизиноновые производные
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
UY30748A1 (es) Compuesto0s novedosos
DOP2011000176A (es) Compuestos organicos
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
GT200900027A (es) Compuestos organicos
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
CU23774A3 (es) Inhibición de arni de expresión de alfa-enac
EA201170772A1 (ru) Органические соединения
UY30610A1 (es) Moduladores de mglur5
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
BRPI0820391A2 (pt) Composto, composição e métodos de modulação da expressão do fator 7
GT200600117A (es) Nuevos compuestos farmaceuticos
EA201170832A1 (ru) Пуриновые соединения
MX336958B (es) Metodos y composiciones para modular la hemostasia.
NO20090994L (no) 2-aminobenzoxazol karboxamider som 5HT3 modulatorer
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
WO2006078886A3 (en) Compounds and compositions as wnt signaling pathway modulators